IMGN632 is a novel ADC that is a potential treatment for AML, blastic plasmacytoid dendritic cell neoplasm, myelodysplastic syndrome, B-cell acute lymphocytic leukemia and other CD123-positive malignancies.

IMGN632 utilizes novel payload, linker and antibody technology and, in preclinical models, demonstrated an impressive therapeutic window. It is in Phase I clinical testing.

Learn more about our IMGN632 Clinical Trials
Learn more about IMGN632 Publications